Genmab — August 2017
-
Meget gerne spørgsmål til Q&A allerede i dag.
-
jkj mange for dit svar. Men baseret på de rapporterede salgstal i USD, vil dette ikke medføre et øget target til årets omsætning i USD?
-
Legolas er det Nordeas
12 måneders kursmål? -
Nordeas kurstarget er "her og nu". Banken har før nedskrevet alene pga dollarkursen.
-
Måske på tide de reagerer på $kursen kunne jeg sige, det tog lidt tid. Bliver spændende at aflæse i årsregnskabet om CFO magter at dæmme op for faldende $ og viser at han er sin astronomiske hyre værd.........jeg tvivler, men måske jeg tager fejl igen igen:-) Hvis jeg mod forventning alligevel skulle få ret, så burde han fratages sin støtte af warrants til flere 100 mill$.
-
"Biopharma stages a strong recovery - EPR"
https://www.europeanpharmaceuticalreview.com/news/65096/biopharma-strong-recovery/ -
Nordea: Our updated forecasts reflect significant FX headwind from H2 2017 onwards, which also results in a ~5% cut to our DCF-based target price down to DKK 1,510 (1,577) per share. We maintain our Buy rating on Genmab but acknowledge that the stock may be range-bound until ESMO in September and 1L Darzalex data
-
Nordea: We have updated our model to reflect the recent significant depreciation of the USD, which takes down our estimates by 5-10% near-term and 3-5% longer-term.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind